Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 2.92% to close at $44.39 with the total traded volume of 4.46 Million shares. Alnylam Pharmaceuticals, Inc. (ALNY) reported that expects to report top-line data from the APOLLO Phase 3 trial in mid-2017 and additional results in late 2017. Assuming positive Phase 3 data, Alnylam plans to submit a New Drug Application and Marketing Authorisation Application for patisiran at year-end 2017.
Patisiran is an investigational RNAi therapeutic in development for the treatment of hereditary ATTR amyloidosis with polyneuropathy.AlnylamPharma expects the ATLAS program to consist of three separate Phase 3 trials. The company plans to initiate the ATLAS Phase 3 program in early 2017 and present data from ongoing fitusiran trials in mid- and late 2017.Alnylam also plans to continue support of The Medicines Company’s advancement of inclisiran into Phase 3 studies in early and mid-2017. The firm has institutional ownership of 92.10%, while insider ownership included 0.30%. Its price to sales ratio ended at 95.83. ALNY attains analyst recommendation of 2.40 with week performance of 5.68%.
Viacom, Inc. (NASDAQ:VIAB) [Trend Analysis] climbed reacts as active mover, shares a gain 0.89% to traded at $35.22 and the percentage gap between open changing to regular change was 0.69%. Sumner Redstone will step down from the Viacom (VIAB) BOD in February after the company holds its annual meeting, Viacom said Friday.The move marks another milestone for the company that has been in turmoil for more than a year.
Redstone, the controlling shareholder of Viacom and CBS, “will continue to participate in board meetings in a non-voting role,” Viacom said in a Securities and Exchange Commission filing. Redstone will remain chairman emeritus, the role he segued to last February after shareholders raised concerns about his status as chairman amid reports of his failing health. The firm’s current ratio calculated as 1.20 for the most recent quarter. The firm past twelve months price to sales ratio was 1.13 and price to cash ratio remained 37.17. As far as the returns are concern, the return on equity was recorded as 36.00% and return on investment was 12.40% while its return on asset stayed at 6.40%. The firm has total debt to equity ratio measured as 2.79.